Contineum Therapeutics, Inc. Class A Common Stock
CTNM
$17.27+3.85%
Delayed · as of Aug 25, 2026, 3:44 PM ET
Mkt cap
$429.57M
EV/Sales
N/A
P/E ratio
N/A
FY2024 Revenue
N/A
EPS (H1 2026)
$-0.79
Gross Margin (FY2024)
N/A
Profit Margin (FY2024)
N/A
Beta
0.89
Div yield
N/A
Sector
Healthcare
No recent filings in cache.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
Latest reported CTNM revenue for 2024-12-31 was $0. Net income was -$42.3M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. CTNM currently screens at market cap $429.6M.
Use this CTNM research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full CTNM income, balance, and cash tables.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company in the Healthcare sector.
Latest cached Contineum Therapeutics, Inc. Class A Common Stock (CTNM) net income for Dec 31, 2024 was -$42.3M. Statements: https://lician.com/financials/ctnm
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) market capitalization is $429.6M on the latest cached snapshot.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) cached previous close $16.63; day range $16.47 – $17.51; volume 562,779. Session quote: https://lician.com/quote/ctnm
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) latest cached earnings event is "CTNM earnings" on Aug 4, 2026. Earnings calendar: https://lician.com/earnings